Stiefel Sues Cobrek, Perrigo Over Generic Acne Drug

Law360, New York (March 13, 2009, 12:00 AM EDT) -- Stiefel Laboratories Inc. has sued Cobrek Pharmaceuticals Inc. and its partner Perrigo Co. over their plans to develop a generic version of the acne treatment Evoclin, which Stiefel claims would infringe two of its patents for the topical antibiotic.

In a complaint filed Friday in the U.S. District Court for the District of Delaware, Stiefel and its Australian research subsidiary, Stiefel Research Australia Pty. Ltd., allege Cobrek and Perrigo have infringed its patents by filing an abbreviated new drug application with the U.S. Food and Drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.